C
C01AA04 Digitoxin
[C01AA] Digitalis glycosides
[C01A] CARDIAC GLYCOSIDES
[C01] CARDIAC THERAPY
[C] Cardiovascular system
Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
---|---|---|---|---|---|---|---|---|
MEMBRANE POTENTIAL | 0.16±0.05 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
MEMBRANE POTENTIAL | 0.06 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
MEMBRANE POTENTIAL | rat | hepatocytes | MMP assay | Negative | IC50 | 163 | ||
Pictogram | Signal | Statements | Precautionary Statement Codes |
---|---|---|---|
Danger |
H301: Toxic if swallowed [Danger Acute toxicity, oral] H331: Toxic if inhaled [Danger Acute toxicity, inhalation] H373 **: Causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure] |
P260, P261, P264, P270, P271, P301+P310, P304+P340, P311, P314, P321, P330, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) | |
Danger |
Aggregated GHS information provided by 202 companies from 6 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H301+H331 (76.24%): Toxic if swallowed or if inhaled [Danger Acute toxicity, oral acute toxicity, inhalation] H301 (98.02%): Toxic if swallowed [Danger Acute toxicity, oral] H331 (100%): Toxic if inhaled [Danger Acute toxicity, inhalation] H373 (99.5%): Causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P260, P261, P264, P270, P271, P301+P310, P304+P340, P311, P314, P321, P330, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) | |
Danger |
H301: Toxic if swallowed [Danger Acute toxicity, oral] H331: Toxic if inhaled [Danger Acute toxicity, inhalation] H373: Causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure] |
P260, P261, P264, P270, P271, P301+P310, P304+P340, P311, P314, P321, P330, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) | |
Danger |
H301: Toxic if swallowed [Danger Acute toxicity, oral] H331: Toxic if inhaled [Danger Acute toxicity, inhalation] H373: Causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure] |
P260, P261, P264, P270, P271, P301+P310, P304+P340, P311, P314, P321, P330, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) | |
Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
---|---|---|---|---|---|
cat | LDLo | intravenous | 343ug/kg (0.343mg/kg) | Journal of the American Pharmaceutical Association. Vol. 27, Pg. 761, 1938. | |
guinea pig | LDLo | intravenous | 777ug/kg (0.777mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 10, Pg. 195, 1960. | |
man | TDLo | oral | 240ug/kg (0.24mg/kg) | gastrointestinal: nausea or vomiting | Sammlung von Vergiftungsfaellen. Vol. 10, Pg. 141A, 1939. |
rat | LDLo | intravenous | 12mg/kg (12mg/kg) | Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 177, Pg. 60, 1934. | |
pigeon | LDLo | intravenous | 470ug/kg (0.47mg/kg) | Proceedings of the Society for Experimental Biology and Medicine. Vol. 89, Pg. 99, 1955. | |
(3beta,5beta)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-14-hydroxycard-20(22)-enolide | 071D636 | 16732-EP2280955A2 |
16732-EP2280980A1 | 16732-EP2292612A2 | 16732-EP2300441A1 |
16732-EP2301938A1 | 16732-EP2303866A2 | 16732-EP2307386A1 |
16732-EP2315764A2 | 16732-EP2376427A1 | 16732-EP2376433A1 |
3-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-4-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-4-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one | 3-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13 | 3beta-[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyloxy]-14-hydroxy-5beta-card-20(22)-enolide |
3beta-[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyloxy]-14-hydroxy-5beta-card-20(22)-enolide | 4-((1S,2S,5S,11S,7R,10R,14R,15R)-5-{5-[5-((2S,4S,5S,6R)-4,5-dihydroxy-6-methyl (2H-3,4,5,6-tetrahydropyran-2-yloxy))(4S,5S,2R,6R)-4-hydroxy-6-methyl(2H-3,4,5 ,6-tetrahydropyran-2-yloxy)](4S,5S,2R,6R)- | 4-((1S,2S,5S,11S,7R,10R,14R,15R)-5-{5-[5-((2S,4S,5S,6R)-4,5-dihydroxy-6-methyl (2H-3,4,5,6-tetrahydropyran-2-yloxy))(4S,5S,2R,6R)-4-hydroxy-6-methyl(2H-3,4,5 ,6-tetrahydropyran-2-yloxy)](4S,5S,2R,6R)-4-hydroxy-6-methyl(2H-3,4,5,6-tetrah ydropyran-2-yloxy) |
4-((3S,5R,8R,9S,10S,13R,14S,17R)-3-(((2R,4S,5S,6R)-5-(((2S,4S,5S,6R)-5-(((2S,4S,5S,6R)-4,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one | 4-[(1S,2S,5S,7R,10R,11S,14R,15R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11-hydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl]-2,5-dihydrofuran-2-one | 4-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-5H-furan-2-one |
4-hydroxy-6-methyl(2H-3,4,5,6-tetrah ydropyran-2-yloxy)}-11-hydroxy-2,15-dimethyltetracyclo[8.7.0.0<2,7>.0<11,15>]h eptadec-14-yl)-5-hydrofuran-2-one | 5beta,20(22)-Cardenolide-3beta,14-diol-3-(O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-[1-->4]-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-[1-->4]-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy | 6467-EP1441224A2 |
6467-EP2270011A1 | 71-63-6 | A572A148-EC30-47D2-A32A-C9D8A93F8EFC |
ACon0_000319 | ACon1_000610 | AKOS015915863 |
Acedoxin | Asthenthilo | BDBM46356 |
BRD-K63668566-001-01-7 | BRN 0076678 | C06955 |
C41H64O13 | CAS-71-63-6 | CCG-208538 |
CCRIS 7116 | CHEBI:28544 | CHEMBL254219 |
CS-5502 | Card-20(22)-enolide, 3-((O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-.beta.-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- | Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy, (3beta,5beta)- |
Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- | Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- | Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1.fwdarw.4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1.fwdarw.4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)-; |
Cardidigin | Cardigin | Carditalin |
Carditoxin | Caswell No. 349 | Coramedan |
Cristapurat | Crystalline | Crystalline digitalin |
Crystodigin | Crystodigin (TN) | D00297 |
D0542 | DB01396 | DSSTox_CID_2933 |
DSSTox_GSID_22933 | DSSTox_RID_76793 | DTXSID0022933 |
De-Tone | Digicor | Digilong |
Digimerck | Digipural | Digisidin |
Digitalin, crystalline | Digitaline | Digitaline cristallisee |
Digitaline nativelle | DigitoXin, USP | Digitoksim |
Digitoksin | Digitophyllin | Digitossina |
Digitossina [DCIT] | Digitoxigenin tridigitoxoside | Digitoxigenin-tridigitoxosid |
Digitoxigenin-tridigitoxosid [German] | Digitoxin (JAN/USP/INN) | Digitoxin [USP:INN:BAN:JAN] |
Digitoxin, >=92% (HPLC), powder | Digitoxin, British Pharmacopoeia (BP) Reference Standard | Digitoxin, European Pharmacopoeia (EP) Reference Standard |
Digitoxin, United States Pharmacopeia (USP) Reference Standard | Digitoxina | Digitoxina [INN-Spanish] |
Digitoxine | Digitoxine [INN-French] | Digitoxinum |
Digitoxinum [INN-Latin] | Digitoxoside | Digitoxosidum |
Digitrin | Ditaven | E90NZP2L9U |
EINECS 200-760-5 | EPA Pesticide Chemical Code 097002 | GTPL6782 |
Glucodigin | HSDB 215 | HY-B1357 |
LMST01120018 | Lanatoxin | MCULE-8291336831 |
MCULE-9783596421 | MEGxp0_001901 | MFCD00003686 |
MLS000069787 | Mono-digitoxid | Mono-digitoxid [German] |
Mono-glycocard | Monodigitoxoside | Myodigin |
NCGC00142623-02 | NCGC00142623-03 | NCGC00142623-04 |
NCGC00142623-05 | NCGC00142623-05_C41H64O13_Crystodigin | NCGC00159428-02 |
NCGC00255265-01 | NSC 7529 | NSC-7529 |
NSC7529 | Natigal | Purodigin |
Purodigin, crystalline | Purpurid | Q-100791 |
Q423890 | REGID_for_CID_441207 | SBI-0051348.P003 |
SC-43721 | SCHEMBL20940 | SMP1_000096 |
SMR000058529 | SR-01000721879-2 | ST072187 |
Tardigal | Tox21_111659 | Tox21_111659_1 |
Tox21_302269 | Tri-digitoxoside [German] | UNII-3899510F8M component WDJUZGPOPHTGOT-XUDUSOBPSA-N |
UNII-E90NZP2L9U | Unidigin | WDJUZGPOPHTGOT-XUDUSOBPSA-N |
Y0070 | Z1558290128 | ZINC95862733 |
cid_441207 | digitoxin |